European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application - Pfizer (NYSE:PFE), V

Valneva SE (NASDAQ:VALN) stock is surging on Friday after the company and its partner Pfizer Inc.

(NYSE:PFE) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, their Lyme disease vaccine candidate.

The EMA will now commence its assessment of the application.

Clinical Trial Results The application for PF-07307405 is supported by encouraging efficacy data from the Phase 3 VALOR clinical trial.

The trial evaluated the vaccine candidate's ability to prevent Lyme disease in individuals aged five and older.

European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application - Pfizer (NYSE:PFE), V

Other newsrooms on this story

Related reading

Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization…

Valneva vola a Parigi, vaccino Lyme supera primo step procedurale Ema

Pfizer Lyme Disease Vaccine Shows 70% Efficacy, But Misses Statistical Goal

Lyme disease vaccine shows strong results. How it works.

EMA to study potential vaccine for Lyme disease | Euractiv

Valneva corre a Parigi con vaccino contro malattia di Lyme